{"id":"ara-c-mitoxantrone-daunorubicin-thioguanin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression/neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1417019","moleculeType":"Small molecule","molecularWeight":"517.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ara-C is a cytidine analog that inhibits DNA polymerase and incorporates into DNA to disrupt replication. Daunorubicin and mitoxantrone are topoisomerase II inhibitors that intercalate into DNA and prevent strand separation. Thioguanine is a purine analog that inhibits nucleotide synthesis. Together, these agents target rapidly dividing leukemic cells through multiple mechanisms of DNA damage and replication inhibition.","oneSentence":"This is a combination chemotherapy regimen that includes cytarabine (Ara-C), mitoxantrone, daunorubicin, and thioguanine, which work together to inhibit DNA synthesis and induce apoptosis in leukemic cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:12.012Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute leukemia in adults"}]},"trialDetails":[{"nctId":"NCT01382147","phase":"PHASE3","title":"Evaluation of \"Dose-dense Therapy\" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Prof. Dr. Wolfgang Hiddemann","startDate":"2009-07-01","conditions":"Acute Myeloid Leukemia","enrollment":396}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ara-C, Mitoxantrone, Daunorubicin, Thioguanin","genericName":"Ara-C, Mitoxantrone, Daunorubicin, Thioguanin","companyName":"Prof. Dr. Wolfgang Hiddemann","companyId":"prof-dr-wolfgang-hiddemann","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination chemotherapy regimen that includes cytarabine (Ara-C), mitoxantrone, daunorubicin, and thioguanine, which work together to inhibit DNA synthesis and induce apoptosis in leukemic cells. Used for Acute myeloid leukemia (AML), Acute leukemia in adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}